成大生物(688739.SH):韶關高騰要約收購期滿 股票停牌
格隆匯4月3日丨成大生物(688739.SH)公佈,公司於2025年3月3日披露了《遼寧成大生物股份有限公司要約收購報吿書》,韶關高騰向成大生物除遼寧成大股份有限公司之外的其他所有股東,發出收購其持有的無限售條件流通股的全面要約,本次預定要約收購股份數量為183,971,587股,佔公司總股本的44.18%,要約收購價格為25.51元/股。要約收購期限為2025年3月5日至2025年4月3日。截至2025年4月3日,本次要約收購期限屆滿,因需進一步確認要約收購結果,根據《上海證券交易所上市公司自律監管指引第4號——停復牌》《上海證券交易所科創板股票上市規則》等相關規定,經向上海證券交易所申請,公司股票於2025年4月7日(星期一)停牌一個交易日,並將在要約收購結果公吿當日復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.